Pacific Biosciences Q4 Sales Up 13.8% to $44.65M, Loss Narrows
Pacific Biosciences posted Q4 CY2025 revenue of $44.65 million, up 13.8% year-on-year and 3.7% above analyst estimates. The non-GAAP loss per share narrowed to $0.12 and operating margin improved to –92.3% from –387% a year earlier.
1. Q4 Performance Highlights
Pacific Biosciences delivered Q4 CY2025 revenue of $44.65 million, representing a 13.8% increase from the prior year and a 3.7% beat versus forecasts. Adjusted EPS was a loss of $0.12 per share, outperforming consensus by 10.8%, while adjusted EBITDA loss narrowed to $41.01 million.
2. Profitability Trends
The company’s operating margin improved significantly to –92.3%, up from –387% in the same quarter last year, driven by enhanced product mix and controlled operating expenses. Despite continued unprofitability, this marks a major step toward margin stabilization after five years of deep losses.
3. Market Valuation and Outlook
Pacific Biosciences holds a market capitalization of $555.5 million and has achieved a five-year revenue CAGR of 15.2%, though recent two-year trends showed declines. Analysts now anticipate 11.5% revenue growth over the next 12 months, reflecting confidence in new product adoption and sequencing demand.